A. Mori

1.3k total citations · 1 hit paper
30 papers, 860 citations indexed

About

A. Mori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Mori has authored 30 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in A. Mori's work include Advanced Breast Cancer Therapies (19 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). A. Mori is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). A. Mori collaborates with scholars based in Italy, United States and Canada. A. Mori's co-authors include Richard S. Finn, Dongrui R. Lu, Véronique Dièras, Karen A. Gelmon, Hope S. Rugo, Johannes Ettl, Eric Gauthier, Nadia Harbeck, Cynthia Huang Bartlett and Shrividya Iyer and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

A. Mori

28 papers receiving 850 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

2019 286 citations Hope S. Rugo, Richard S. Finn et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Mori Italy	12	729	680	259	213	65	30	860
Aurelio Castrellon United States	12	392 0.5×	429 0.6×	210 0.8×	125 0.6×	102 1.6×	34	655
Georgina Garnica Jaliffe United States	3	1.0k 1.4×	905 1.3×	395 1.5×	273 1.3×	98 1.5×	3	1.1k
Karen Rodriguez-Lorenc United States	8	655 0.9×	600 0.9×	289 1.1×	179 0.8×	84 1.3×	19	793
P. Gómez Pardo Spain	9	367 0.5×	566 0.8×	158 0.6×	71 0.3×	91 1.4×	27	716
Juan Pablo Zarate United States	11	541 0.7×	462 0.7×	255 1.0×	148 0.7×	131 2.0×	29	678
Keun-Seok Lee South Korea	4	524 0.7×	475 0.7×	233 0.9×	144 0.7×	66 1.0×	7	623
Sarah Sammons United States	16	399 0.5×	466 0.7×	168 0.6×	97 0.5×	119 1.8×	92	706
T Taran United States	6	561 0.8×	505 0.7×	248 1.0×	113 0.5×	233 3.6×	13	742
Isabelle Desmoulins France	15	205 0.3×	361 0.5×	271 1.0×	52 0.2×	84 1.3×	75	624
Esther Holgado Spain	15	367 0.5×	757 1.1×	169 0.7×	40 0.2×	129 2.0×	42	870

Countries citing papers authored by A. Mori

Since Specialization

Citations

This map shows the geographic impact of A. Mori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Mori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Mori more than expected).

Fields of papers citing papers by A. Mori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Mori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Mori. The network helps show where A. Mori may publish in the future.

Co-authorship network of co-authors of A. Mori

This figure shows the co-authorship network connecting the top 25 collaborators of A. Mori. A scholar is included among the top collaborators of A. Mori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Mori. A. Mori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fein, Luis, Nicolas Lazaretti, John R. Benfield, et al.. (2023). Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation. 43(9). 699–706. 3 indexed citations

Finn, Richard S., Hope S. Rugo, Karen A. Gelmon, et al.. (2021). Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. The Oncologist. 26(5). e749–e755. 40 indexed citations

Rugo, Hope S., Richard S. Finn, Véronique Dièras, et al.. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment. 174(3). 719–729. 286 indexed citations breakdown →

Rugo, Hope S., Richard S. Finn, Karen A. Gelmon, et al.. (2019). Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer. 20(2). e173–e180. 24 indexed citations

Dièras, Véronique, Nadia Harbeck, Anil A. Joy, et al.. (2019). Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. The Oncologist. 24(12). 1514–1525. 55 indexed citations

Gelmon, Karen A., Massimo Cristofanilli, Hope S. Rugo, et al.. (2019). Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer. The Breast Journal. 26(3). 368–375. 10 indexed citations

Mukai, Hirofumi, In Hae Park, Norikazu Masuda, et al.. (2019). Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology. 5(5). 1–19. 55 indexed citations

Dièras, Véronique, Hope S. Rugo, Patrick Schnell, et al.. (2018). Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. JNCI Journal of the National Cancer Institute. 111(4). 419–430. 67 indexed citations

Turner, Nicholas C., Richard S. Finn, Miguel Martín, et al.. (2018). Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology. 29(3). 669–680. 69 indexed citations

10.

Rugo, HS, RS Finn, Véronique Dièras, et al.. (2018). Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups. Cancer Research. 78(4_Supplement). P5–21. 11 indexed citations

11.

Rugo, Hope S., Véronique Dièras, Karen A. Gelmon, et al.. (2018). Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Annals of Oncology. 29(4). 888–894. 106 indexed citations

12.

Dièras, Véronique, Nadia Harbeck, Anil A. Joy, et al.. (2017). PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L). Annals of Oncology. 28. v96–v96. 6 indexed citations

13.

Finn, Richard S., Karen A. Gelmon, Johannes Ettl, et al.. (2017). Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis. Annals of Oncology. 28. v79–v80. 2 indexed citations

14.

Im, S.-A., Hirofumi Mukai, Norikazu Masuda, et al.. (2016). 116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Annals of Oncology. 27. ix35–ix35. 5 indexed citations

15.

Rugo, Hope S., Véronique Dièras, Karen A. Gelmon, et al.. (2016). Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2. Annals of Oncology. 27. vi69–vi69. 6 indexed citations

16.

Watanabe, K., et al.. (2008). Preliminary study on genetic population of the Japanese eight-barbel loach in the upper Kokai River basin, Tochigi prefecture [Japan] using micropsatellite DNA.

17.

Corsini, Chiara, Michele Ghielmini, Patrizia Mancuso, et al.. (2000). Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. British Journal of Cancer. 82(3). 524–528. 4 indexed citations

18.

Saccomanno, S., C. Aschele, Alfredo Guglielmi, et al.. (1995). 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 35(4). 339–342. 5 indexed citations

19.

Guglielmi, Alfredo, C. Aschele, A. Mori, et al.. (1995). In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.. PubMed. 1(11). 1337–44. 5 indexed citations

20.

Mori, A., Sergio Bertoglio, C. Aschele, et al.. (1993). Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemotherapy and Pharmacology. 33(2). 179–180. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact